Related Experiment Video
Updated: Jul 29, 2026

Real-time Measurement of Epithelial Barrier Permeability in Human Intestinal Organoids
Published on: December 18, 2017
Pyk2 inhibitor prevents epithelial hyperpermeability induced by HMGB1 and inflammatory cytokines in Caco-2 cells
Takumi Konno1, Takayuki Kohno1, Maki Miyakawa1,2
1Department of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Abstract:
The non-receptor protein tyrosine kinase 2β (Pyk2) phosphorylated tricellular tight junction (tTJ) molecules angulin-1/LSR and tricellulin (TRIC) and the inhibitor PF-431396 (PF43) suppress angulin-1/LSR and TRIC recruitment to tTJs. The disruption of the intestinal epithelial barrier by high mobility group box 1 (HMGB1) and the inflammatory cytokines TNFα and IFNγ contributes to downregulation of angulin-1/LSR and TRIC in 2.5D culture of Caco-2 cells as a novel model of inflammatory bowel disease (IBD). In the present study, to investigate the roles of Pyk2 phosphorylated angulin-1/LSR and TRIC in the intestinal epithelial barrier, 2D and 2.5D cultures of Caco-2 cells were treated with the Pyk2 inhibitor PF-43 with or without HMGB1, inflammatory cytokines TNFα and IFNγ. Treatment with PF-43 increased expression of angulin-1/LSR, phosphorylated AMPK and phosphorylated MAPK and decreased that of phosphorylated JNK, with upregulation of the epithelial barrier and cellular metabolism measured as basal oxygen consumption rate (OCR) and ATP production in 2D culture. Treatment with PF-43 prevented the downregulation of the epithelial barrier by HMGB1 and inflammatory cytokines in 2D culture. Treatment with PF-43 prevented the epithelial hyperpermeability induced by HMGB1 and inflammatory cytokines in 2.5D culture. In 2.5D culture, treatment with PF-43 inhibited the decreases of angulin-1/LSR, TRIC, pJNK, pAMPK and pMAPK induced by HMGB1 and the inflammatory cytokines. Treatment with PF-43 inhibited in part the induced phosphorylation of the serine of angulin-1/LSR and TRIC. Pyk2 inhibitor PF-43 may have potential for use in therapy for IBD via its actions with regard to phosphorylated tTJs and cellular metabolism.
Insights
The Pyk2 inhibitor PF-43 improves intestinal barrier function by modulating tricellular tight junction proteins and cellular metabolism. This suggests PF-43
Area of Science:
- Cell Biology
- Gastroenterology
- Molecular Medicine
Background:
- The non-receptor protein tyrosine kinase 2β (Pyk2) phosphorylates tricellular tight junction (tTJ) proteins angulin-1/LSR and tricellulin (TRIC).
- High mobility group box 1 (HMGB1) and inflammatory cytokines (TNFα, IFNγ) disrupt the intestinal epithelial barrier, downregulating angulin-1/LSR and TRIC.
- Caco-2 cell cultures serve as a model for inflammatory bowel disease (IBD).
Purpose of the Study:
- To investigate the role of Pyk2-phosphorylated angulin-1/LSR and TRIC in maintaining the intestinal epithelial barrier.
- To evaluate the effects of the Pyk2 inhibitor PF-43 on intestinal barrier integrity and cellular metabolism in IBD models.
Main Methods:
- 2D and 2.5D Caco-2 cell cultures were treated with PF-43, HMGB1, TNFα, and IFNγ.
- Assessed epithelial barrier function, cellular metabolism (OCR, ATP production), and protein expression/phosphorylation (angulin-1/LSR, TRIC, JNK, AMPK, MAPK).
Main Results:
- PF-43 treatment upregulated angulin-1/LSR, phosphorylated AMPK, and phosphorylated MAPK, while decreasing phosphorylated JNK in 2D cultures.
- PF-43 enhanced epithelial barrier function and cellular metabolism (OCR, ATP production) in 2D cultures.
- PF-43 prevented HMGB1 and cytokine-induced barrier disruption and hyperpermeability in both 2D and 2.5D cultures, preserving tTJ protein levels and signaling pathways.
Conclusions:
- Pyk2 inhibitor PF-43 demonstrates potential therapeutic value for IBD.
- PF-43 acts by influencing phosphorylated tTJs and improving cellular metabolism.
- PF-43 protects the intestinal epithelial barrier from inflammatory damage.
Related Concept Videos
Gastritis II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology
Inflammatory Bowel Disease II: Ulcerative Colitis

